The novel sulfated oligosaccharide agent PI-88 is being developed by the Australian biotechnology company, Progen Industries Limited, as an anticancer drug. PI-88 is an inhibitor of angiogenesis, that is, the growth of new blood vessels from pre-existing ones surrounding a tumour. PI-88 also blocks the spread of tumour cells (metastasis) by inhibition of the key enzyme heparanase. PI-88 is currently in Phase II trials as a monotherapy and in Phase I as a combination therapy with the cytotoxic drug Docetaxel.